| Q46127174 | A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis |
| Q41588742 | AzaSite® Inhibits Staphylococcus aureus and Coagulase-Negative Staphylococcus Biofilm Formation In Vitro |
| Q34043273 | Azithromycin in DuraSite® for the treatment of blepharitis |
| Q37110822 | Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis |
| Q51783661 | Eyelid cleansing with ointment for obstructive meibomian gland dysfunction. |
| Q36358739 | How to promote and preserve eyelid health |
| Q34015010 | Inadvertent ocular perforation during lid anesthesia for hordeolum removal. |
| Q34277253 | Madarosis: a marker of many maladies |
| Q43092268 | Ophthaproblem. Chalazion |
| Q49546496 | Opinion of the BVA and the DOG on physical therapy of dry eye : July 2017 status |
| Q34325595 | Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study |
| Q35682044 | Tolerability and acceptability of Blephagel: a novel eyelid hygiene aqueous gel. |
| Q35590257 | Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device |
| Q42789151 | Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections |
| Q52907021 | [Meibomian glands : part III. Dysfunction - argument for a discrete disease entity and as an important cause of dry eye]. |